Skip to main content
Premium Trial:

Request an Annual Quote

Roche Non-Exclusively Licenses Melting Curve Tech to Eppendorf

NEW YORK (GenomeWeb News) - Roche Diagnostics has licensed its Melting Curve Analysis technology to Eppendorf, the companies said Tuesday.
 
The non-exclusive agreement allows Eppendorf to develop and commercialize products based on the technology, which is a technique for analyzing PCR products. The deal does not allow Eppendorf to use the IP in human and veterinary in vitro diagnostics.
 
The Melting Curve Analysis technology identifies DNA and is used after PCR. It involves heating the PCR product slowly until each double-stranded DNA rises to its unique melting temperature.  
 
Financial terms of the agreement were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.